Substrate Specificity

Substrate Specificity designates the selectivity of enzymes, receptors, or other binding proteins for particular molecular substrates, determining which molecules undergo catalysis, binding, or transport whilst excluding others based on structural complementarity, chemical properties, and molecular recognition. This fundamental biochemical property arises from active site or binding pocket architecture creating geometric and chemical environments favouring specific substrates.

The pharmaceutical industry extensively characterises substrate specificity throughout drug development, informing target selection, predicting drug metabolism, assessing off-target effects, and designing selective therapeutics. Enzyme inhibitor development requires understanding target specificity, enabling design of molecules recognised by intended enzymes whilst avoiding related family members to prevent off-target toxicity. Kinase inhibitor selectivity is particularly challenging given conserved ATP-binding sites across hundreds of human kinases, with extensive profiling used to identify off-target interactions. Drug metabolism studies characterise cytochrome P450 substrate specificity, predicting clearance pathways and identifying responsible enzymes. Transporter substrate specificity determines absorption, distribution, and elimination. Antibody specificity ensures therapeutic antibodies recognise intended antigens without cross-reactivity. As therapeutic targets diversify and computational approaches predict substrate recognition, substrate specificity characterisation and optimisation remain central to developing safe, effective therapeutics with desired selectivity profiles minimising off-target effects.